<DOC>
	<DOCNO>NCT00928902</DOCNO>
	<brief_summary>This clinical pilot study test hypothesis systemic low-dose IL-2 therapy significantly enhance immunologic efficacy vaccine comprise melanoma peptide plus GM-CSF-in-adjuvant .</brief_summary>
	<brief_title>Trial Evaluation Effect Systemic Low-dose Interleukin-2 ( IL-2 ) Immunogenicity Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor ( GM-CSF ) -In-Adjuvant , Patients With High Risk Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Patients diagnose , cytologic histologic examination , AJCC stage IIB , stage III resect stage IV melanoma . Patients 2 brain metastasis less equal 2 cm surgically remove treat successfully gammaknife eligible . Surgical resection must perform within 6 month prior entry . All patient must : 1 . ECOG performance status 01 , , 2 . Ability willingness give inform consent . Laboratory parameter follow : HLAA1 , A2 A3 ( + ) gp100 ( + ) and/or tyrosinase ( + ) tumor cell ANC &gt; 1000/mm3 , Platelets &gt; 100,000 Hgb &gt; 9 Hepatic : AST ALT 2.5 x upper limit normal ( ULN ) , Bilirubin 2.5 x ULN , Alkaline phosphatase 2.5 x ULN Renal : Creatinine 1.5 x ULN Serology : HIV negative , Hepatitis C negative Exclusion criterion : Patients currently receive cytotoxic Chemotherapy radiation receive therapy within precede 4 week . Patients know suspected allergy component vaccine . Patients receive follow medication study entry within precede 30 day exclude : Agents putative immunomodulating activity ( exception nonsteroidal antiinflammatory agent ) Allergy desensitization injection Corticosteroids , administer parenterally orally topical corticosteroid acceptable Any growth factor , Interleukin 2 , Interferon alfa . Prior melanoma vaccination exclusion criterion give 8 week previously , record , data analysis take account . Other investigational drug investigational therapy also necessarily exclusion criterion , similarly record take account data analysis . Pregnancy possibility become pregnant vaccine administration . Female patient childbearing potential must negative pregnancy test ( urinary serum betaHCG ) prior administration first vaccine dose . Males female must agree , consent form , use effective birth control method course vaccination . This consistent existing standard practice vaccine chemotherapy protocol . Patients medical contraindication potential problem complying requirement protocol , opinion investigator . Patients classify accord New York Heart Association classification system Class II , III IV heart disease . Patients active connective tissue disease require medication , severe autoimmune disease . Patients actively hyperthyroid . Patients uncontrolled diabetes .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>melanoma</keyword>
	<keyword>vaccine</keyword>
	<keyword>peptide</keyword>
	<keyword>adjuvant</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>stage IIB , stage III resect stage IV</keyword>
</DOC>